Essex Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-10,939
| Closed | -$3.45M | – | 413 |
|
|
2023
Q1 | $3.45M | Sell |
10,939
-2,396
| -18% | -$719K | 0.5% | 58 |
|
|
2022
Q4 | $3.85M | Sell |
13,335
-41
| -0.3% | -$12.5K | 0.6% | 46 |
|
|
2022
Q3 | $3.87M | Sell |
13,376
-842
| -6% | -$242K | 0.62% | 44 |
|
|
2022
Q2 | $4.01M | Sell |
14,218
-666
| -4% | -$178K | 0.65% | 41 |
|
|
2022
Q1 | $3.88M | Sell |
14,884
-686
| -4% | -$163K | 0.48% | 55 |
|
|
2021
Q4 | $3.42M | Sell |
15,570
-1,060
| -6% | -$206K | 0.39% | 75 |
|
|
2021
Q3 | $3.02M | Sell |
16,630
-6,933
| -29% | -$1.35M | 0.37% | 83 |
|
|
2021
Q2 | $4.75M | Sell |
23,563
-1,823
| -7% | -$381K | 0.55% | 52 |
|
|
2021
Q1 | $5.46M | Sell |
25,386
-1,068
| -4% | -$235K | 0.67% | 38 |
|
|
2020
Q4 | $6.25M | Sell |
26,454
-12,550
| -32% | -$2.88M | 0.78% | 24 |
|
|
2020
Q3 | $10.6M | Sell |
39,004
-648
| -2% | -$179K | 1.52% | 5 |
|
|
2020
Q2 | $11.5M | Sell |
39,652
-8,700
| -18% | -$2.36M | 1.89% | 5 |
|
|
2020
Q1 | $11.5M | Sell |
48,352
-3,183
| -6% | -$730K | 2.33% | 4 |
|
|
2019
Q4 | $11.3M | Sell |
51,535
-144
| -0.3% | -$29.1K | 1.39% | 9 |
|
|
2019
Q3 | $8.76M | Buy |
51,679
+9,433
| +22% | +$1.67M | 1.26% | 10 |
|
|
2019
Q2 | $7.75M | Hold |
42,246
| – | – | 1.06% | 11 |
|
|
2019
Q1 | $7.77M | Sell |
42,246
-6,704
| -14% | -$1.24M | 1.15% | 14 |
|
|
2018
Q4 | $8.11M | Sell |
48,950
-12,607
| -20% | -$2.18M | 1.27% | 13 |
|
|
2018
Q3 | $11.9M | Sell |
61,557
-3,188
| -5% | -$568K | 1.39% | 9 |
|
|
2018
Q2 | $11M | Buy |
64,745
+6,745
| +12% | +$1.05M | 1.38% | 8 |
|
|
2018
Q1 | $9.45M | Buy |
58,000
+136
| +0.2% | +$22.2K | 1.24% | 12 |
|
|
2017
Q4 | $8.67M | Buy |
57,864
+2,936
| +5% | +$435K | 1.14% | 14 |
|
|
2017
Q3 | $8.35M | Sell |
54,928
-2,285
| -4% | -$344K | 1.13% | 15 |
|
|
2017
Q2 | $7.37M | Buy |
57,213
+19,050
| +50% | +$2.29M | 1.06% | 16 |
|
|
2017
Q1 | $4.17M | Buy |
38,163
+26,388
| +224% | +$2.32M | 0.65% | 36 |
|
|
2016
Q4 | $867K | Sell |
11,775
-9,349
| -44% | -$761K | 0.14% | 179 |
|
|
2016
Q3 | $1.84M | Buy |
+21,124
| New | +$2M | 0.3% | 88 |
|
|
2016
Q1 | – | Sell |
-6,247
| Closed | -$786K | – | 330 |
|
|
2015
Q4 | $786K | Sell |
6,247
-560
| -8% | -$67.6K | 0.12% | 182 |
|
|
2015
Q3 | $709K | Buy |
6,807
+560
| +9% | +$71.9K | 0.12% | 180 |
|
|
2015
Q2 | $771K | Sell |
6,247
-500
| -7% | -$63K | 0.12% | 189 |
|
|
2015
Q1 | $796K | Buy |
6,747
+3,291
| +95% | +$394K | 0.11% | 190 |
|
|
2014
Q4 | $411K | Hold |
3,456
| – | – | 0.06% | 247 |
|
|
2014
Q3 | $388K | Hold |
3,456
| – | – | 0.06% | 257 |
|
|
2014
Q2 | $327K | Sell |
3,456
-2,646
| -43% | -$186K | 0.05% | 287 |
|
|
2014
Q1 | $432K | Sell |
6,102
-452
| -7% | -$35.8K | 0.06% | 260 |
|
|
2013
Q4 | $487K | Buy |
6,554
+1,644
| +33% | +$114K | 0.07% | 272 |
|
|
2013
Q3 | $372K | Sell |
4,910
-67
| -1% | -$5.33K | 0.06% | 284 |
|
|
2013
Q2 | $398K | Buy |
+4,977
| New | +$367K | 0.07% | 240 |
|
Other funds holding VRTX
Essex Investment Management's VRTX Position: Q2 2023 in Review
Essex Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 10,939 shares — an estimated $3.45M sold.
Essex Investment Management first reported a position in VRTX in Q2 2013 and held it in 38 quarters. The position peaked at $11.9M in Q3 2018. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.
- Essex Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
- Essex Investment Management sold 10,939 Vertex Pharmaceuticals shares in Q2 2023, an estimated $3.45M.
- Essex Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 38 quarters.
- Essex Investment Management's Vertex Pharmaceuticals position peaked at $11.9M in Q3 2018.
- 1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.
Based on Essex Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.